Member Profile
Medigen Biotechnology Corp.
Medigen Biotechnology Corp. (MBC) was established in late 1999. The company upholds the vision of “Innovations for a better life” focusing on the development of new therapies for liver diseases and cancers. MBC has now gradually developed into a comprehensive biopharmaceutical corporation with business fields covering cell therapy technology, new drug, molecular diagnostics, precision medicine, cell-based vaccine, biologics and ophthalmic drug.
Product Pipelines
Please move your mouse cursor over abbreviations with periods to see their full names.
Company Milestones
| 2019 | Medigen has entered into exclusive license agreement with Japanese publicly listed company MEDINET to expand Gamma-delta T cell therapy market in Taiwan |
| 2019 | Medigen and Cellxpert Biotechnology Crop. have entered into agreement under which Medigen will grant an exclusive worldwide license except Taiwan to Cellxpert for PI-88 |
| 2020 | Medigen has obtained approval from Ministry of Health and Welfare for Natural Kill (NK) cell therapy |
| 2022 | Enrollment of first patient in phase I study of Magicell-NK |
| 2023 | Medigen has obtained approval from Ministry of Health and Welfare for Gamma-Delta T (GDT) cell therapy |
| 2024 | Medigen and NKure in collaboration to develop Medigen’s natural killer cell therapy (Magicell-NK) in India |
| 2024 | Medigen has applied to the Taiwan Food and Drug Administration (TFDA) for Phase I/II clinical trial of allogeneic natural killer cells (Magicell-NK) |
| 2024 | The first participant has been enrolled in the investigator-initiated Phase II clinical trial of the new drug OBP-301 in the United States |